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OBJECTIVES: In common with other chronic conditions, fibromyalgia syndrome
(FMS) adversely affects Health-Related Quality of Life (HRQoL) and functional sta-
tus. FMS often results in disability and profoundly affects the performance of daily
activities, both at work and at home. This study was conducted to assess the
patient-level burden among subjects with FMS. METHODS: A prospective, obser-
vational studywas carried out on FMSpatients from44medical centers throughout
Korea. HRQoL scores were obtained using the Short Form (SF)-36 Health Survey. To
estimate recent 3month healthcare and non-healthcare cost, and productivity loss
of FMS patients, participants completed a standardized questionnaire. Cost items
mainly included healthcare cost such as outpatient, pharmacy, inpatient, and ori-
ental medicine; non-healthcare cost such as traffic expenses, nursing cost, com-
plementary and alternative medicine. Cost included insurance-covered cost as
well as patient’s out-of-pocket expenses during 3months. To estimate productivity
loss due to morbidity, days away from work due to FMS were also investigated.
RESULTS: Among 1,040 FMS patients who completed the questionnaire, female
was 92% (n957). Approximately 45.7% of patients had rheumatic diseases. HRQoL
physical component mean scores were determined as 35.97.5, and mental com-
ponent mean scores were determined as 34.612.6. Number of out-patient visits
within 3 months was 4.06.5. Total costs over 3 months were 1,6092,055 USD.
Within 3 months, 23.4% and 91.2% of patients with FMS had been away from work
and reported the decreased work productivity, respectively. In the preceding 3
months, FMS patientsmissed 20 (SD28.1) days of work, left work early an average
of 28 (SD31.0) days, and accomplished less at work an average of 65 (SD30.0)
days. CONCLUSIONS: Our results suggested that the patient-level burden among
FMS sufferers in Korea is significant, evidenced by negative effect on health-related
quality of life, health resource use and work/activity limitations.
PSY12
BASELINE CHARACTERISTICS AND PRE–INDEX TOTAL HEALTH CARE AND
RHEUMATOID ARTHRITIS-RELATED COSTS IN PATIENTS RECEIVING
GOLIMUMAB THERAPY
Carter C1, Tandon N1, Smith D2
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2IMS Health Incorporated,
Watertown, MA, USA
OBJECTIVES: Golimumab was recently approved by the Food and Drug Adminis-
tration onApril 24, 2009 for use in patients with rheumatoid arthritis (RA), psoriatic
arthritis (PsA), or ankylosing spondylitis (AS). The objective of this study was to
compare baseline demographic and clinical characteristics and pre-index total/RA-
related healthcare costs in patients receiving golimumab with/without biologic
experience. METHODS: The IMS LifeLink™ Health Plan database was utilized to
identify patients with an: age 18 years at index; index golimumab pharmacy
claim started 4/24/2009-10/31/2009;1 RA, PsA, or AS ICD-9 diagnosis code; and 24
months pre- and 2 months post-index continuous enrollment. RESULTS: A total
of 282 patients (n206 with pre-index biologic experience) receiving golimumab
were identified; mean SD age was 52 12; 72% female. No significant differences
in demographic characteristics existed between patients with/without biologic ex-
perience. The top three rheumatologic conditions were RA (79%), PsA (26%), and AS
(10%). Hypertension (45%), dyslipidemia (40%), and diabetes (17%) were the most
prevalent comorbidities prior to starting golimumab. Pre-index total healthcare
costs (mean, median) were significantly higher for biologic experienced patients
($59,979, $46,075) compared to non-biologic experienced patients ($21,002, $12,662;
p0.001). Among the 178 patients with an RA diagnosis only, pre-index total RA-
related costs (mean, median) were significantly higher for patients with biologic
experience ($29,701, $27,464) than those without ($6,045, $1,937; p0.001). Overall
mean  SD RA-related medication costs ($17,193  $16,619) were greater than
RA-related outpatient or inpatient costs ($5,239  $14,912 and $225  $3,001,
respectively). CONCLUSIONS:When examining baseline clinical characteristics of
patients receiving golimumab, results showed that the majority of patients were
diagnosed with RA, and had concomitant hypertension, dyslipidemia, or diabetes.
Most patients received another biologic prior to golimumab. Biologic experienced
patients were more costly at baseline. These characteristics should be adjusted for
in comparative analyses including golimumab.
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THE COST OF OBESITY AND ITS MAJOR COMORBIDITIES: ANALYSIS FROM A
COMMERCIAL CLAIMS DATABASE
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OBJECTIVES: To determine payments made by commercial healthcare providers
for adults diagnosed with obesity, and those comorbid with any combination of
certain chronic conditions: diabetes mellitus (DM), hypertension, depression,
and/or congestive heart failure (CHF).METHODS:We utilized a 10% random sam-
pling from MarketScan, a commercial claims and encounters database
(n12,416,190). The study population (n50,717) was limited to thosewho: (1) were
adults age 18-64; (2) filed claims between 2006-2007; (3) had at least one inpatient
visit, one outpatient visit, or one emergency department visit; and, (4) were given a
primary or secondary diagnosis of obesity. Persons were identified and categorized
if they had one ormore comorbid diagnoses (DM, hypertension, depression, and/or
CHF) in addition to obesity. After adjusting for age and gender, we calculated the
mean total net expenditures (in $US 2007) for each combination of comorbid con-
ditions. All calculations were performed in Stata. RESULTS: Among those diag-
nosedwith obesity, themean net expenditures for services were $1799 per patient.
Persons diagnosed with obesity and other comorbidities observed an increase in
total net expenditures. Obesity and hypertension observed the highest increase
among single comorbidities at $4298. For persons with obesity and two other co-
morbidities, DM and depression was the highest at $14364. The most expensive
condition in the study sample was obesity, DM, hypertension and depression at
$14843. All results were statistically significant at the 95% confidence level.
CONCLUSIONS: Compared to the average medical claim, persons diagnosed with
obesity along with other common chronic conditions experience significant in-
creases in healthcare costs. These costs are often drivenhigher by the time spent as
inpatients. In many cases, obesity may be the cause of other chronic conditions
that result in these high costs. Thus, by controlling and reducing the prevalence of
obesity, we may see significant decreases in healthcare expenditures.
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OBJECTIVES: Patients managing chronic non-cancer pain with cytochrome P450
(CYP450)-metabolized opioid (codeine, fentanyl, hydrocodone, methadone, oxy-
codone, tramadol) analgesics who concurrently take another CYP450-metabolized
medication experience a drug-drug exposure (DDE), which puts them at risk for a
pharmacokinetic drug-drug interaction (DDI). This study examined whether patients
with an incident DDE with the potential to cause a DDI had greater healthcare costs
compared to similar patients without such exposure. METHODS: Propensity score
matchingwas used to control for baseline differences in an insured population chron-
ically using these opioid analgesics during the period, January 1, 2004 throughDecem-
ber 31, 2008. Estimates of the predicted likelihood of a DDE occurrence for thematch-
ing model were derived from patient age, gender, geographical location, number of
unique concurrentmedications, co-morbidities, services utilization, and total costs in
the six-months pior to the index date. Comparisonsweremade between 122,586 DDE
and 122,586 no-DDE patients. RESULTS: Comparisons yielded mean total costs six
months after an incident DDE that were significantly higher for younger ( 65 years
old) patients with DDE versus matched no-DDE patients ($8,165 vs. $7,498, respec-
tively, resulting in a difference of $667, p0.01). Similarly among older ( 65years old)
patients, mean total costs at six months were significantly higher for patients with
DDE compared to matched no-DDE patients ($9,598 vs. $9,030, respectively, resulting
in a difference of $568, p0.01). The direction, magnitude and significance of these
differences persisted after sensitivity analyses. CONCLUSIONS: Although it is impos-
sible to establish causal relationships in claims database studies, this study demon-
strates a strong association of the economic consequences of DDEs that are avoidable.
Sinceconcurrentexposure tomultipledrugsmetabolized through theCYP450enzyme
system may be relatively common, policy decisions should include consideration of
the use of long-acting opioids that are not metabolized through the CYP450 pathway.
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OBJECTIVES: Although hemophilia may have a large economic impact on patients
and healthcare systems, published estimates of costs for care of U.S. hemophilia
patients are sparse. The objective of this study is to estimate average annual costs
of health care for hemophilia patients in the United States, stratified according to
the influence of age, type of hemophilia [A (factor VIII deficiency) versus B (factor
IX)], presence of neutralizing alloantibody inhibitors, and exposure to blood-borne
viral infections.METHODS: Data from the MarketScan® Commercial and Medicare
Research Databases were used for the period 2002-2008 to identify cases of hemo-
philia and to estimatemedical expenditures during 2008. RESULTS: A total of 1,164
male hemophilia patients were identified, 933 with hemophilia A and 231 with
hemophilia B. Their average annual costs for health care in 2008 were $155,136.
Average annual costs for 30 (3%) hemophilia A patients with an inhibitor were 5
times higher than for other hemophilia patients, approximately $697,000 and
$144,000, respectively. Clotting factor concentrate accounted for 70%–82% of total
costs. Average costs for 207 adult patients with HCV or HIV infectionwere 1.5 times
higher than those for adults without infection. A subset of adults with viral infec-
tion had particularly high use of factor concentrate and costs. CONCLUSIONS:
Hemophilia treatment is associated with a significant economic burden, particu-
larly for patients with neutralizing alloantibody inhibitors who require bypassing
agents for treatment. The excess costs of care associated with blood-borne viral
infection are concentrated among a subset of hemophilia patients.
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OBJECTIVES:Obesity, defined as bodymass index (BMI) 30, is amajor contributor
to increased morbidity, mortality, and healthcare expenditures. There is a ten-
dency for obese individuals to continually gain weight over their lifetimes. How-
ever, neither the strength of this tendency nor its economic consequences are well
understood. We constructed a health outcomes model from a societal perspective
to assess this.METHODS: Our model projected lifetime trajectories for BMI, death,
cost, and quality-adjusted life years (QALYs). Using these projections, we com-
puted the net economic value of potential weight loss for an individual given base-
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line characteristics: Age, Sex, and BMI. We used existing literature and public da-
tasets to estimate the parameters of the model. For the BMI trajectory, we utilized
existing literature on pooled databases of the individuals’ BMI over time. For the
probability of death, we constructed life tables by estimating the 5-year probability
of death using a logistic regression model using data from the National Health
Institute Survey linked with National Death Index (NHIS-NDI) between 1997 and
2005. For costs and QALYs, we useMedical Expenditure Panel Survey Panels 6-10 to
estimate hedonic linear regressions in each period. Costs and QALYs were dis-
counted at 3%. RESULTS: In the base case— for a 45 year-old female—the expected
age of death for baseline BMI of 25, 35, or 45 was 83, 80, and 77, respectively. The
projected difference in discounted lifetime healthcare costs between this non-
obese (BMI 25) person and someone BMI 45 is about $26,000. If the loss inQALYs
were valued at $100,000/QALY, the net economic value loss is projected at $271,000.
CONCLUSIONS: Obesity is associated with higher medical costs, lower quality of
life, and reduced life expectancy. The societal cost of delivering effective weight
loss interventions to obese Americans should be considered in the context of these
lifetime outcomes.
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OBJECTIVES: ITP is characterized by reduced platelet counts and increased risk of
bleeding. Romiplostim, a first-in-class thrombopoietin mimetic, safely increases
and sustains platelet counts in most adult patients with chronic ITP for as long as
needed, while reducing the need for concurrent and emergency medications. We
evaluated treatment costs per overall platelet response with romiplostim  con-
current treatment vs. placebo  concurrent treatment in chronic adult ITP, from a
Public Mexican Healthcare perspective.METHODS: Overall response, defined as 
4 weekly platelet responses (50x109/L ) from weeks 2 to 25, was derived from two
randomized parallel trials with splenectomised and non-splenectomised patients
over period of 24 weeks. All patients were allowed to enter on concurrent ITP
medication (danazol, corticosteroids, azathioprine) and receive rescue medication
(eg, intravenous immunoglobulin). Treatment costs included intervention, rescue
medication and management of bleeding-related events during one year period.
Unitary costs were obtained from the 2010 Official Price List of the Public Health-
care System in Mexico ($MXP). Mean treatment cost per response was calculated
for splenectomized and non-splenectomized patients. RESULTS:Cost per response
was lower for romiplostim compared to placebo. Overall response rates were 79%
for romiplostim and 0% for placebo in splenectomized patients and 88% for romi-
plostim vs. 14% for placebo in non-splenectomized patients. Mean treatment costs
were MXP$574,580 for romiplostim and MXP$301,218 for placebo in splenecto-
mized patients and MXP$402,083 for romiplostim and MXP$180,692 for placebo in
non-splenectomized patients. Cost per response were MXP$727,317 for romiplos-
tim and infinite cost per response for placebo in splenectomized patients and
MXP$456,912 for romiplostim and MXP$1,290,655 for placebo in non-splenecto-
mized patients. Themain cost-offsetswere due to reduced immunoglobulin rescue
use. CONCLUSIONS: Given the limited number of effective therapies in ITP, romi-
plostimdemonstrates an important and cost-efficient option for both non-splenec-
tomised and splenectomised patients for the Mexican Public Healthcare System.
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A DECISION ANALYSIS MODEL EXPLORING THE RESULTS OF A PHASE II TRIAL
OF ELTROMBOPAG FOR PATIENTS WITH CHRONIC HEPATITIS C, CIRRHOSIS
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OBJECTIVES: Thrombocytopenia may prevent chronic hepatitis C (CHC) patients
from initiating or maintaining anti-viral therapy. Eltrombopag is a thrombopoietin
receptor agonist currently undergoing phase III trials for treatment of CHC-related
thrombocytopenia. This study examines the cost-effectiveness of eltrombopag in
CHC patients with cirrhosis and thrombocytopenia.METHODS: A two-part model
was developed to estimate quality adjusted life years(QALYs) gained with and
without eltrombopag for a hypothetical population of 50-year-old, white,male CHC
patientswith thrombocytopenia and cirrhosiswho are otherwise eligible to initiate
anti-viral therapy. A decision tree followed the first 48 weeks of anti-viral therapy
for patients receiving eltrombopag (30,50,or 75mg dose) versus a placebo con-
trolled, wait-and-see (W&S) strategy. Lifetime outcomes of anti-viral therapy suc-
cess or failure were projected using a Markov model. Eltrombopag probabilities
were taken from a Phase II trial; other probabilities and costs were derived from
published literature. Model outcomes are presented as incremental cost effective-
ness ratios (ICERs). A probabilistic sensitivity analysis was performed to analyze
parameter uncertainty. RESULTS: Successive eltrombopag dosing strategies were
associated with incremental increases in cost and QALYs. All strategies were cost-
effective at a threshold of $50,000/QALY gained. The 75mg strategy weakly domi-
nated the 50mg and 30mg strategies and had an ICER of $27,496 compared to the
W&S strategy. Results were robust to variation among input parameters.
CONCLUSIONS: The results of this study support the use of eltrombopag as a
cost-effective option in CHC patients with thrombocytopenia. Patients on eltrom-
bopag aremore likely to complete antiviral therapy, leading to increased quality of
life and decreased future costs over a lifetime. More studies are needed to analyze
the safety of eltrombopag and to provide more accurate estimates of its effect on
platelet counts and patient withdrawal from antiviral therapy.
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OBJECTIVES: This study aimed to assess incremental cost-effectiveness of VMP vs
MPR-R in patients newly diagnosed with multiple myeloma (MM), ineligible for
ASCT, with average age of 70 years. METHODS: A Markov model from US payer’s
perspective was developed to assess cost-effectiveness of VMP vs MPR-R for treat-
ment of MM. The model included seven health states: responses (multiple), treat-
ment-free/maintenance, progression, second-line treatment, and death. Monthly
transition probabilities were estimated from patient-level data (VISTA) for VMP
andMP and frompublished data (MM-015) forMPR-R. Costs included drug,medical,
adverse event, second-line treatment, and resource utilization in 2010 US-dollar
value. State-specific utilities were derived from patient-level EQ-5D using US-spe-
cific weights. Effectiveness was expressed in LYs and QALYs. Costs and effective-
ness were discounted at 3%. ICER was calculated for VMP vs MPR-R over 20-year
horizon (lifetime). In the base case, the MPR-R vs MP hazard ratio (HR) for PFS was
0.499 and that for OS was 1, as the survival benefit with MPR-R vs MP was not
observed in MM-015. One-way sensitivity analyses were conducted for key param-
eters to assess the general robustness of themodel. RESULTS: Base-case results for
VMP vs.MPR-R showed: $119,102 vs $248,358 for directmedical costs; 4.187 years vs
3.409 years for LYs; cost of R maintenance was $107,047. VMP was associated with
reduced costs and better outcomes compared with MPR-R; VMP costs approxi-
mately 50% less than MPR-R and seems to provide slightly more QALYs (0.567) on
average. Sensitivity analyses supported the robustness ofmodel findings and iden-
tified the MPR-R vs MP HR for OS as a key driver; only when this HR was 0.24 did
MPR-R become cost-effective vs VMP at $100,000 per QALY. CONCLUSIONS: VMP
had lower costs and better health outcomes compared to MPR-R. R maintenance
showed little additional benefit.
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OBJECTIVES: Ankle sprain causes walking limitation, pain and consequently, eco-
nomic losses. The purpose of this study was to estimate the cost-effectiveness
from a societal perspective of sequential use of parecoxib/celecoxib for pain man-
agement associated with ankle sprain in adults. METHODS: A Markov model was
performed to estimate health and economic consequences during a time horizon
of 45 days (3-day cycles). Effectiveness measures were: percentage of patients re-
porting pain reduction, percentage of patients reporting50% pain reduction from
baseline, reduction of length of stay (LOS) and reduction in the number of treat-
ment retirements due adverse events. Transition probabilities were obtained from
a meta-analysis employing international published literature. Doses of compara-
tors were: diclofenac (75mg bid) followed by diclofenac (100mg bid); parecoxib
(40mg bid) followed by celecoxib (200mg bid) and ketorolac (30mg qid) followed by
ketorolac po (10mg tid) as the reference. Parenteral and oral forms were adminis-
tered for two and five days, respectively. Resource use was obtained from Social
SecurityMexican Institute databases (n1,395 records). Direct costswere extracted
from institutional official sources and indirect costs from a validated survey ap-
plied to patients. Costs included: hospitalization, drugs, medical procedures, im-
aging, adverse events management, disability benefits, productivity losses, and
out-of-pocket expenses. Probabilistic sensitivity analyseswere performed employ-
ing bootstrapping techniques. Acceptability curves were constructed. RESULTS:
Parecoxib/celecoxib, ketorolac and diclofenac costs per patient were: US$440.77
[95%CI US$425.65-US$455.88], US$526.08 [US$509.97-US$542.20] and US$815.43
[US$790.18-US$840.68], respectively (p0.05). Parecoxib/celecoxib exhibits the low-
est LOS (0.69 days [0.67–0.71] (p0.05)) and number of treatment discontinuations
(16/1000 patients). Acceptability curves showed that parecoxib/celecoxib will be
cost-effective with 90% of confidence at a willingness to pay closer to US$0.
CONCLUSIONS: Parecoxib/celecoxib is the less costly treatment to manage pain
associated with moderate ankle sprain in Mexico; as well it represents a cost-
saving alternative in LOS reduction and treatment discontinuation regarding com-
peting alternatives.
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COST-EFFECTIVENESS ANALISYS OF TREATMENT WITH AMFEPRAMONE
(DIETHYLPROPION) IN OBESITY IN MEXICO
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1Iteliness Consulting, Mexico City, Mexico, 2Hospital Infantil de México Federico Gómez, Mexico
City, Mexico, 3Panamerican University, Mexico City, Mexico
OBJECTIVES:The treatment guidelines of obesity at theMexican Institute for Social
Security (IMSS) consider the pharmacological treatment together with the change
in health habits a proper option in cases of obese patients (BMI 30 kg/m2). With
the withdrawal of Sibutramine of the mexican market, Diethylpropion (Amfepra-
mone) emerge as a good candidate to fill the void of a scheme to control and reduce
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